{
    "Trade/Device Name(s)": [
        "Elecsys AFP"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K220176",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981282"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOJ"
    ],
    "Summary Letter Date": "September 15, 2022",
    "Summary Letter Received Date": "January 21, 2022",
    "Submission Date": "January 20, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Alpha-fetoprotein"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Li-Heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas e immunoassay analyzers",
        "cobas e 601 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Elecsys AFP electrochemiluminescence immunoassay to quantify alpha-fetoprotein in serum and plasma for management of non-seminomatous germ cell tumors",
    "Indications for Use Summary": "Immunoassay for the in vitro quantitative determination of alpha-fetoprotein in human serum and plasma to aid in the management of patients with non-seminomatous germ cell tumors, intended for use on cobas e immunoassay analyzers",
    "fda_folder": "Immunology"
}